Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.

Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, Zhang A, Tsang FH, Wong CL, Ng IO, Wong CC, Wong CM. · 2019

Read Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. by Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, Zhang A, Tsang FH, Wong CL, Ng IO, Wong CC, Wong CM. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6794322.txt.

Description

Wei and co-authors used a genome-wide CRISPR screen to find what drives sorafenib resistance in liver cancer. Sorafenib is the standard drug for advanced hepatocellular carcinoma, but resistance is common. Screening knocked out genes one by one to see which loss resensitized tumors. One gene stood out: PHGDH, the first enzyme of the serine synthesis pathway.

Sorafenib itself switches this pathway on by raising PHGDH. Disabling PHGDH starved the pathway, cutting serine and protective molecules. Harmful oxygen radicals then rose, and cancer cells died under sorafenib. An inhibitor called NCT-503 worked with sorafenib to abolish tumor growth in mice. The trick also held for two related approved drugs.

Catalog record

CREATORWei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, Zhang A, Tsang FH, Wong CL, Ng IO, Wong CC, Wong CM.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6794322

Browse the full library · About the Tower of Babel